LCTX
Price
$1.00
Change
+$0.02 (+2.04%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
230.64M
Earnings call today
PDSB
Price
$1.09
Change
-$0.02 (-1.80%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
50.74M
2 days until earnings call
Interact to see
Advertisement

LCTX vs PDSB

Header iconLCTX vs PDSB Comparison
Open Charts LCTX vs PDSBBanner chart's image
Lineage Cell Therapeutics
Price$1.00
Change+$0.02 (+2.04%)
Volume$1.51K
Capitalization230.64M
PDS Biotechnology
Price$1.09
Change-$0.02 (-1.80%)
Volume$4.6K
Capitalization50.74M
LCTX vs PDSB Comparison Chart in %
Loading...
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LCTX vs. PDSB commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LCTX is a Hold and PDSB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (LCTX: $0.98 vs. PDSB: $1.11)
Brand notoriety: LCTX and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LCTX: 23% vs. PDSB: 52%
Market capitalization -- LCTX: $230.64M vs. PDSB: $49.82M
LCTX [@Biotechnology] is valued at $230.64M. PDSB’s [@Biotechnology] market capitalization is $49.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $96.01B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LCTX’s FA Score shows that 0 FA rating(s) are green whilePDSB’s FA Score has 1 green FA rating(s).

  • LCTX’s FA Score: 0 green, 5 red.
  • PDSB’s FA Score: 1 green, 4 red.
According to our system of comparison, LCTX is a better buy in the long-term than PDSB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LCTX’s TA Score shows that 3 TA indicator(s) are bullish while PDSB’s TA Score has 3 bullish TA indicator(s).

  • LCTX’s TA Score: 3 bullish, 4 bearish.
  • PDSB’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, PDSB is a better buy in the short-term than LCTX.

Price Growth

LCTX (@Biotechnology) experienced а -0.09% price change this week, while PDSB (@Biotechnology) price change was +2.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

LCTX is expected to report earnings on Aug 12, 2025.

PDSB is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LCTX($231M) has a higher market cap than PDSB($50.7M). LCTX YTD gains are higher at: 95.900 vs. PDSB (-31.902). LCTX has higher annual earnings (EBITDA): -20.72M vs. PDSB (-33.08M). LCTX has more cash in the bank: 47.9M vs. PDSB (40M). LCTX has less debt than PDSB: LCTX (2.24M) vs PDSB (19M). LCTX has higher revenues than PDSB: LCTX (9.56M) vs PDSB (0).
LCTXPDSBLCTX / PDSB
Capitalization231M50.7M456%
EBITDA-20.72M-33.08M63%
Gain YTD95.900-31.902-301%
P/E RatioN/AN/A-
Revenue9.56M0-
Total Cash47.9M40M120%
Total Debt2.24M19M12%
FUNDAMENTALS RATINGS
LCTX vs PDSB: Fundamental Ratings
LCTX
PDSB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
3787
P/E GROWTH RATING
1..100
62100
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (28) in the Pharmaceuticals Major industry is in the same range as LCTX (44) in the null industry. This means that PDSB’s stock grew similarly to LCTX’s over the last 12 months.

LCTX's Profit vs Risk Rating (90) in the null industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that LCTX’s stock grew similarly to PDSB’s over the last 12 months.

LCTX's SMR Rating (96) in the null industry is in the same range as PDSB (99) in the Pharmaceuticals Major industry. This means that LCTX’s stock grew similarly to PDSB’s over the last 12 months.

LCTX's Price Growth Rating (37) in the null industry is somewhat better than the same rating for PDSB (87) in the Pharmaceuticals Major industry. This means that LCTX’s stock grew somewhat faster than PDSB’s over the last 12 months.

LCTX's P/E Growth Rating (62) in the null industry is somewhat better than the same rating for PDSB (100) in the Pharmaceuticals Major industry. This means that LCTX’s stock grew somewhat faster than PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LCTXPDSB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
87%
Momentum
ODDS (%)
Bearish Trend 4 days ago
83%
N/A
MACD
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 19 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 11 days ago
82%
Bearish Trend 12 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BORT36.99N/A
N/A
Bank of Botetourt (Buchanan, VA)
CRRTF0.41N/A
N/A
Crescita Therapeutics Inc
VLPNY5.70N/A
N/A
Voestalpine AG
OKIEF6.66N/A
N/A
OKI Electric Industry Co., Ltd.
GWLIF38.86-0.11
-0.30%
Great West Lifeco, Inc.

LCTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with ARCT. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LCTX
1D Price
Change %
LCTX100%
+3.53%
ARCT - LCTX
37%
Loosely correlated
-0.58%
PYXS - LCTX
36%
Loosely correlated
-0.93%
MGNX - LCTX
35%
Loosely correlated
-4.35%
BEAM - LCTX
34%
Loosely correlated
-1.34%
PDSB - LCTX
33%
Loosely correlated
-0.89%
More

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with ARCT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
-0.89%
ARCT - PDSB
49%
Loosely correlated
-0.58%
IDYA - PDSB
45%
Loosely correlated
+3.08%
RXRX - PDSB
45%
Loosely correlated
-0.92%
DYN - PDSB
45%
Loosely correlated
N/A
SYRE - PDSB
43%
Loosely correlated
N/A
More